|
Age (years)
|
|
Mean ± SD
|
58.1 ± 7.0
|
59.4 ± 5.7
|
|
Median (range)
|
57 (50–73)
|
58.5 (51–70)
|
|
Female sex, n (%)
|
9 (53)
|
15 (75)
|
|
Primary progressive, n (%)
|
10 (59)
|
10 (50)
|
|
Clinical progression in the year prior to enrolment, n (%)
|
10 (59)
|
16 (80)
|
|
Disease duration
|
|
Mean ± SD
|
14.2 ± 9.6
|
14.9 ± 11.5
|
|
Median (range)
|
11 (4–34)
|
11.5 (5–45)
|
|
EDSS
|
|
Median
|
6
|
6
|
|
Range
|
2.5–7.0
|
3.5–7.0
|
|
9-Hole Peg Test (seconds)
|
|
Median
|
23.15
|
20.86
|
|
Range
|
13.95–32.7
|
14.3–30.1
|
|
Timed 25-ft walk test (seconds)
|
|
Median
|
13.47
|
10.48
|
|
Range
|
5.6–89
|
7.6–34.6
|
|
Not able to complete, n (%)
|
1 (5.6)
|
4 (20)
|
|
Paced Auditory Serial Addition Test z-score
|
|
Mean + SD
|
−1.96 ± 1.48
|
−1.63 ± 1.57
|
|
Multiple Sclerosis Functional Composite
|
|
Mean ± SD
|
−0.17 ± 0.59
|
0.20 ± 0.35
|
|
Median
|
−0.14
|
− 0.01
|
|
Range
|
−2.23
|
−0.88
|
|
Symbol Digit Modalities Test z-score
|
|
Mean ± SD
|
−0.88 ± 0.99
|
0.03 ± 0.66
|
|
Retinal nerve fibre layer thickness (μm)
|
|
Mean ± SD
|
89.97 ± 15.49
|
90.28 ± 12.86
|
|
MRI activity (gadolinium-enhancing lesions), n (%)
|
0 (0)
|
0 (0)
|
|
Normalized brain volume (mm3 ± SD)
|
1,288,183 ± 86,721
|
1,311,701 ± 93,647
|
|
Normalized white matter volume (mm3 ± SD)
|
662,732 ± 51,640
|
665,999 ± 48,708
|
|
Normalized grey matter volume (mm3 ± SD)
|
625,451 ± 41,492
|
645,702 ± 49,755
|
|
Brain parenchymal fraction ± SD
|
0.95 ± 0.02
|
0.95 ± 0.02
|
